medRxivGenetic & Genomic MedicinePreprint
From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges
Florencia GilibertoiD, Paula Inés BuonfiglioiD, Gabriel Capellino, Carmen Llames MassiniiD, Viviana DalamóniD, Leonela N. LuceiD, Micaela CarcioneiD
Abstract
Pompe disease is an autosomal recessive disorder caused by GAA variants leading to acid alpha-glucosidase deficiency. Diagnosis is challenging due to the variable phenotypic presentation and overlap with other conditions. Traditionally, diagnosis relies on measuring enzyme activity, but next-generation sequencing (NGS) advancements have improved accuracy. However, interpreting variants is complex, especially because pseudodeficiency alleles mimic disease-causing variants. We present two patients harboring the pseudodeficiency allele NM_000152.5(GAA):c.271G>A, p.Asp91Asn, which is confusing due to inaccurate reports and results related to enzymatic activity. The first case was a recently published controversial case of a 700-year-old mummy in which the authors classified the variant as pathogenic. The second patient had symptoms compatible with late-onset Pompe disease and was homozygous for the variant. We aimed to determine the correct variant classification using GAA:c.271G>A as a model and to achieve a genetic diagnosis of the second patient. This variant was analyzed following international guidelines (ACMG-AMP) and reviewed with the Lysosomal Diseases Variant Curation Expert Panel. The second patient underwent NGS. We demonstrated that GAA:c.271G>A meets the criterion of being classified as benign for Pompe. Additionally, the second patient carried a heterozygous pathogenic PABPN1 variant associated with oculopharyngeal muscular dystrophy, which better explained the clinical features. This underscores the importance of expanding the genetic analysis in the presence of pseudodeficiency alleles that can mask the true cause of the disease and highlights the fact that an accurate diagnosis should adhere to guidelines on variant curation to reduce the risk of misdiagnosis, which could result in inadequate care and risky medical decisions. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/24314698v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@12a720borg.highwire.dtl.DTLVardef@1a53d15org.highwire.dtl.DTLVardef@14d4729org.highwire.dtl.DTLVardef@7b0186_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: DNA methylation
- assay: whole-exome sequencing
- research focus: variant effect prediction
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The molecular basis for Pompe disease revealed by the structure of human acid α-glucosidase
Derrick Deming, Karen Lee, … Scott C. Garman·bioRxiv·Nov 1, 2017
- AlphaGenome identifies a deep intronic variant in a family with PLA2G6-associated neurodegeneration: Closing the diagnostic gap in rare genetic diseases
Sarah J. Eger, Greizy López, … Kenneth S. Kosik·medRxiv·Jun 18, 2026
- Sequence determinants of pathogenicity in glucose-6-phosphatase linked to glycogen storage disease type 1a
Richard A. Stein, Emily M. Hawes, … Derek P. Claxton·bioRxiv·Jul 28, 2026
- CRISPR-Mediated Generation and Characterization of a Gaa Homozygous c.1935C>A (p.D645E) Pompe Disease Knock-in Mouse Model Recapitulates Human Infantile Onset-Pompe Disease
Shih‐hsin Kan, Jeffrey Y. Huang, … Raymond Wang·bioRxiv·May 30, 2022
- Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinsons disease cohort
Oscar E.E. Graham, Toni L. Pitcher, … Martin Alexander Kennedy·Parkinsonism & Related DisordersPeer-reviewed·Nov 29, 2019
- Is Gauchian genotyping of GBA1 variants reliable?
Nahid Tayebi, Jens Lichtenberg, … Ellen Sidransky·Communications BiologyPeer-reviewed·May 9, 2025